Analyst Research Report Snapshot

Title:

bioMerieux SA

Price:

$175.00

Provider:

MarketLine (a Datamonitor Company)

Date:

08 Apr 2014

Pages:

42

Type:

AcrobatPDF

Companies referenced:

BIOX.PA

Available for Immediate Download
Summary:

bioMerieux SA - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company. Features: - Detailed information on bioMerieux SA required for business and competitor intelligence needs - A study of the major internal and external factors affecting bioMerieux SA in the form of a SWOT analysis - An in-depth view of the business model of bioMerieux SA including a breakdown and examination of key business segments - Intelligence on bioMerieux SA’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about bioMerieux SA, such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: bioMerieux (or ‘the company’), a part of the Institut Merieux group, is a provider of in-vitro diagnostics for medical and industrial applications. It operates in Europe, the Middle East, Africa, North America, Asia Pacific and Latin America. The company is headquartered in Marcy l'Etoile, France, and employed 7,285 people as of December 31, 2012. The company recorded revenues of E1,569.8 million ($2,018.4 million*) during the financial year ended December 2012 (FY2012), an increase of 10% over FY2011. The operating profit of the company was E235 million ($302.2 million*) during FY2012, a decrease of 4.2% compared with FY2011. The net profit was E134.4 million ($172.8 million*) in FY2012, a decrease of 15% compared with FY2011. *Calculated using a constant conversion rate of E1 = $1.2858 for the financial year ended December 31, 2012. Reasons to Purchase: - Gain understanding of bioMerieux SA and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess bioMerieux SA as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on bioMerieux SA’s business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.